<PubmedArticle>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">20819898</PMID>
<DateCompleted>
<Year>2010</Year>
<Month>10</Month>
<Day>27</Day>
</DateCompleted>
<DateRevised>
<Year>2017</Year>
<Month>11</Month>
<Day>16</Day>
</DateRevised>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1098-4275</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>126</Volume>
<Issue>4</Issue>
<PubDate>
<Year>2010</Year>
<Month>Oct</Month>
</PubDate>
</JournalIssue>
<Title>Pediatrics</Title>
<ISOAbbreviation>Pediatrics</ISOAbbreviation>
</Journal>
<ArticleTitle>Iron supplements reduce the risk of iron deficiency anemia in marginally low birth weight infants.</ArticleTitle>
<Pagination>
<MedlinePgn>e874-83</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1542/peds.2009-3624</ELocationID>
<Abstract>
<AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Low birth weight infants are at risk for iron deficiency (ID). Most LBW infants have marginally low birth weight (MLBW, 2000-2500 g) and it is not known whether they benefit from iron supplements. The objective of this trial was to study the effects of iron supplementation in MLBW infants.</AbstractText>
<AbstractText Label="METHOD" NlmCategory="METHODS">In a randomized controlled trial, we assigned 285 healthy, MLBW infants to receive iron supplements at a dose of 0 (placebo), 1, or 2 mg/kg per day between 6 weeks and 6 months of age. Hemoglobin levels, ferritin levels, transferrin saturation, mean cell volume, and transferrin receptor levels were analyzed at 6 months. Growth and morbidity were monitored.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">Iron supplementation resulted in significant dose-dependent effects on hemoglobin and all iron status indicators at 6 months. The prevalence of ID at 6 months was 36% in the placebo group, 8.2% in the 1 mg/kg per day group, and 3.8% in the 2 mg/kg per day group (P&lt;.001). The prevalence rates of ID anemia (IDA) were 9.9%, 2.7%, and 0%, respectively (P=.004). Among infants who were exclusively breastfed at 6 weeks, the prevalence of IDA was 18% in the placebo group. There were no significant differences between groups in growth or morbidity.</AbstractText>
<AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">MLBW infants have relatively high risks of ID and IDA, especially if they are breastfed. Iron supplementation at 2 mg/kg per day from 6 weeks to 6 months reduces this risk effectively, with no short-term adverse effects on morbidity or growth.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Berglund</LastName>
<ForeName>Staffan</ForeName>
<Initials>S</Initials>
<AffiliationInfo>
<Affiliation>Umeå University, Department of Clinical Sciences, Division of Pediatrics, SE-901 85 Umeå, Sweden.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Westrup</LastName>
<ForeName>Björn</ForeName>
<Initials>B</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Domellöf</LastName>
<ForeName>Magnus</ForeName>
<Initials>M</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<DataBankList CompleteYN="Y">
<DataBank>
<DataBankName>ClinicalTrials.gov</DataBankName>
<AccessionNumberList>
<AccessionNumber>NCT00558454</AccessionNumber>
</AccessionNumberList>
</DataBank>
</DataBankList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016449">Randomized Controlled Trial</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2010</Year>
<Month>09</Month>
<Day>06</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Pediatrics</MedlineTA>
<NlmUniqueID>0376422</NlmUniqueID>
<ISSNLinking>0031-4005</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D005296">Ferrous Compounds</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D006454">Hemoglobins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014168">Transferrin</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>818ZYK7N91</RegistryNumber>
<NameOfSubstance UI="C022943">ferrous succinate</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>E1UOL152H7</RegistryNumber>
<NameOfSubstance UI="D007501">Iron</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>AIM</CitationSubset>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018798">Anemia, Iron-Deficiency</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000517">prevention &amp; control</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001942">Breast Feeding</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004311">Double-Blind Method</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005296">Ferrous Compounds</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000008">administration &amp; dosage</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006454">Hemoglobins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000032">analysis</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007223">Infant</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D007230">Infant, Low Birth Weight</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007231">Infant, Newborn</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007234">Infant, Premature</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007501">Iron</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000097">blood</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014168">Transferrin</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000032">analysis</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData>
<History>
<PubMedPubDate PubStatus="entrez">
<Year>2010</Year>
<Month>9</Month>
<Day>8</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed">
<Year>2010</Year>
<Month>9</Month>
<Day>8</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline">
<Year>2010</Year>
<Month>10</Month>
<Day>28</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
<ArticleId IdType="pubmed">20819898</ArticleId>
<ArticleId IdType="pii">peds.2009-3624</ArticleId>
<ArticleId IdType="doi">10.1542/peds.2009-3624</ArticleId>
</ArticleIdList>
</PubmedData>
</PubmedArticle>